The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation
The purpose of this study was to assess efficacy, safety and PK in metastatic colorectal cancer (mCRC) given HLX208 (BRAF V600E inhibitor).
Metastatic Colorectal Cancer|mCRC
DRUG: HLX208
ORR, Objective response rate(assessed by independent radiological review committee (IRRC) based on the RECIST Version 1.1), up to 2 years
PFS, Progression-free survival (PFS) (assessed by IRRC and the investigator as per RECIST v1.1 ), from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 2 years|OS, Overall survival, from the date of first dose until the date of death from any causeï¼Œassessed up to 2 years
The purpose of this study was to assess efficacy, safety and PK in metastatic colorectal cancer (mCRC) given HLX208 (BRAF V600E inhibitor).